RENX to present at 40th JP Morgan Healthcare Conf.

RNS Number : 4318X

Renalytix PLC

05 January 2022

Renalytix plc

("Renalytix" or the "Company")

Renalytix to Present at 40^th Annual J.P. Morgan Virtual Healthcare Conference

LONDON and SALT LAKE CITY, January 5, 2022 - Renalytix plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will be presenting at the upcoming 40^th Annual J.P. Morgan Virtual Healthcare Conference.

Renalytix's management is scheduled to present on Wednesday, January 12 2022, at 2:15 p.m. EST. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at investors.renalytix.com.

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company's lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore

Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams

Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth		Mob: 07980 541 893 / 07584 391 303

CapComm Partners
Peter DeNardo			Tel: 415-389-6400 or investors@renalytix.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASSSFULEESELF

RENX to present at 40th JP Morgan Healthcare Conf. - Renalytix PLC | RNS | Ticker